Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020 ... May 14
New subgroup analyses for first-line treatment of advanced renal cell carcinoma with BAVENCIO®* (avelumab) in combination with axitinib... Sep 23
Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study Phase II INSIGHT 2 study now open for enrollment for ... Sep 12
Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in ... Sep 11
-Advertisements-